Intravenous bisphosphonates are a standard therapeutic option in the prevention of skeletal-related events in metastatic breast and prostate cancer as well as multiple myeloma with bone involvement. Denosumab represents a new class of medications that inhibits the RANK ligand and is currently being evaluated to prevent skeletalrelated events. S keletal-related events are a common complication of malignancy and can increase overall morbidity and mortality.
Intravenous bisphosphonates are a standard therapeutic option in the prevention of skeletal-related events in metastatic breast and prostate cancer as well as multiple myeloma with bone involvement. Denosumab represents a new class of medications that inhibits the RANK ligand and is currently being evaluated to prevent skeletalrelated events.
S keletal-related events are a common complication of malignancy and can increase overall morbidity and mortality. 1 Bone metastases are closely linked to skeletal-related events and are common in patients with metastatic disease. Nearly 70% of patients with breast or prostate cancer develop bone metastases. 2 Cooperberg et al 3 assessed the incidence of bone metastases over a 6-month period after primary treatment for localized prostate cancer, where the number of bone metastases was nearly 3% in just 6 months. Multiple myeloma is another condition that commonly affects bone, where patients characteristically develop lytic bone lesions due to an alteration in the bone remodeling process. 4 Bone metastases are thought to develop through hematogenous spread from the primary tumor, where the cancer cells adhere to the bone and then grow. Adhesive molecules, growth factors, and nutrients make the bone an ideal environment for cancer cells to grow; however, the presentation of the metastatic lesions vary. Bone metastases are typically classifi ed as osteolytic lesions or osteoblastic lesions.
In osteolytic bone metastases, osteoclasts are predominantly performing bone resorption near malignant cells while osteoblasts are suppressed, which is evident in multiple myeloma. In osteoblastic bone metastases, an increase in osteoblast activity leads to irregular bone trabeculae, which is common in prostate cancer. 5 Bone metastases of osteoblastic and osteolytic nature can lead to different skeletal effects, but most studies do not differentiate; instead they use a composite endpoint termed skeletal complications or skeletal-related events.
Skeletal-related events are commonly defi ned by pathologic fractures, spinal cord compression, surgery for the prevention and treatment of pathologic fractures or spinal cord compression, or radiation for bone pain.
Hypercalcemia is an additional complication commonly seen in patients with bone metastases, where pharmacologic options have also been used.
Hypercalcemia can occur from both direct osteolytic affects on the bone and indirect humoral effects. In breast cancer, 92% of metastatic bone disease patients secrete parathyroid hormone-related peptide that stimulates bone resorption and subsequent hypercalcemia. The risk of developing a pathologic fracture with metastatic bone disease is nearly 4 times more likely to occur within 5 years than in a patient without metastatic bone disease. 6 Additionally, metastatic bone disease can be painful, and the onset and severity of pain may be related to the direct resorption effects of the tumor, which may be relieved with pharmacologic treatment or radiation therapy. 7 Fractures have a true effect on the morbidity and mortality of the patient. Saad 
PROSTATE CANCER
Bisphosphonates are a pharmacologic option in bone metastases that inhibit osteoclast-mediated bone resorption by decreasing osteoclast activity and interfering with attachment, differentiation, and survival. Zoledronic acid 4 mg every 3 weeks is currently approved in metastatic bone disease for the prevention of skeletal-related events, which include pathologic fractures, radiation or surgery on the bone, spinal cord compression, or hypercalcemia. 8 Zoledronic acid was evaluated in androgen-independent prostate cancer with bone metastases, where it was demonstrated to decrease the risk of skeletal-related events by 11% compared to placebo at 15 months. 9 Additionally, pamidronate was evaluated in androgenindependent prostate cancer and symptomatic bone metastases, where patients received pamidronate 90 mg every 3 weeks or placebo for 27 weeks. 10 At 27 weeks, no difference was found in pain scores, analgesic use, or skeletal-related events. These data suggest that zoledronic acid is effective in androgen-independent prostate cancer with bone metastases in the prevention of skeletal-related events, while other bisphosphonates may lag in effi cacy.
BREAST CANCER
Bisphosphonates have also been evaluated in the prevention of skeletal-related events in metastatic breast cancer patients with osteolytic lesions, where pamidronate was one of the fi rst bisphosphonates approved in this setting. Hortobagyi et al 11 evaluated 380 metastatic breast cancer patients with lytic bone lesions on current chemotherapy treatment with either 90 mg of pamidronate monthly or placebo. At 12 months, skeletal-related events decreased signifi cantly by 13% with pamidronate therapy, with an overall incidence of 43% and 56% in the pamidronate and placebo groups, respectively. Subsequently zoledronic acid was evaluated in a phase III noninferiority study evaluating metastatic breast cancer and multiple myeloma patients with osteolytic bone metastases. 12 Patients were given zoledronic acid or pamidronate every 3 to 4 weeks for 1 year. Patients in the zoledronic acid and pamidronate groups had similar rates of skeletal-related events, with 44% and 43% of patients at 12 months, respectively, in the breast cancer patient cohort on chemotherapy. 12 
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MULTIPLE MYELOMA
Bisphosphonates are also a therapeutic option in the management of multiple myeloma, as these patients traditionally develop lytic lesions. Rosen et al 14 evaluated the incidence of skeletal-related events in a combined population of multiple myeloma and metastatic breast cancer patients with bone metastases as described previously. After 1 year of treatment, zoledronic acid reduced the risk of developing skeletal complications by an additional 16% (Pϭ.030) in the combined population at 25 months when compared to pamidronate. However, when comparing the risk of skeletal complications in the multiple myeloma group, no difference was demonstrated. This study demonstrates that bisphosphonates are effective at reducing skeletal-related events in patients with lytic lesions in multiple myeloma; however, one bisphosphonate has not been shown to be superior to the other in this setting.
ADVERSE EVENTS OF BISPHOSPHONATES
A common toxicity with bisphosphonate use is nephrotoxicity, which is cited to occur in 6% and 8% of patients given pamidronate and zoledronic acid, respectively. Dose adjustments are warranted for patients with impaired renal function at baseline, as well as temporary interruption of therapy for signifi cant increases in serum creatinine for both pamidronate and zoledronic acid. 15 The practice guidelines in multiple myeloma recommend regular monitoring of serum creatinine as well as monitoring electrolytes and hemoglobin/hematocrit. 16 A commonly discussed adverse event of bisphosphonates is osteonecrosis of the jaw. The estimated risk of osteonecrosis of the jaw is approximately 3.5% to 11%. The current update committee on bisphosphonates in multiple myeloma has recommended that all patients receive a comprehensive dental examination and preventive dentistry prior to initiating treatment. 16 Data regarding the use of bisphosphonates in multiple myeloma suggest that not all bisphosphonates are equal in risk of developing osteonecrosis of the jaw. A retrospective analysis conducted by Zervas et al 17 reported that 11.02% of multiple myeloma patients receiving a bisphosphonate developed osteonecrosis of the jaw. A Cox regression analysis revealed a 9.5-fold greater risk of osteonecrosis of the jaw with zoledronic acid compared to pamidronate alone (Pϭ.042). Additional toxicities may include myalgia, arthralgia, and fl u-like symptoms (Table) . 15 
NEW PHARMACOLOGIC OPTIONS
Bisphosphonates are pyrophosphate compounds that adhere to bone and prevent bone resorption by inhibiting and killing osteoclasts. 8 Denosumab, currently approved for postmenopausal osteoporosis, is a potential new treatment that has a different mechanism of action. Denosumab is a fully human monoclonal antibody that binds to the receptor activator for nuclear factor ␤ ligand (RANKL), which is a soluble or transmembrane protein that binds the RANK receptor. When RANKL binds with the RANK receptors on osteoclast precursors, it induces the formation of osteoclasts and promotes survival and activation, therein promoting bone resorption and bone lesions. The parathyroid hormone-related peptide, which can be produced by malignant cells (eg, breast cancer), stimulates RANKL production and subsequently stimulates osteoclasts. Osteoclasts that are stimulated by RANKL also secrete growth factors, which may stimulate both tumor and multiple myeloma cell growth such as interleukin-6 in multiple myeloma. 5 Denosumab activity has been evaluated in the setting of prostate cancer with bone metastases. A phase III, randomized, double-blind trial compared denosumab 120 mg subcutaneously every 4 weeks or zoledronic acid 4 mg intravenously every 4 weeks in 1901 androgen-independent prostate cancer patients with bone metastases. Denosumab demonstrated superiority by reducing both the time to the fi rst skeletal-related event and the rate of multiple skeletalrelated events (hazard ratio, 0.82; 95% confi dence interval [CI], 0.71-0.94). 18 These data suggest that denosumab is effective in preventing skeletalrelated events and may be superior to bisphosphonates.
Denosumab has also been evaluated in metastatic breast cancer with bone metastases in patients who have received prior bisphosphonate therapy, as well as in patients who have not received prior bisphosphonate therapy. A phase III, randomized, double-blind study in 2046 bisphosphonate-naive breast cancer patients compared denosumab 120 mg subcutaneously to zoledronic acid 4 mg intravenously every 4 weeks. 19 The median time to onset of fi rst skeletal-related event was 26.5 months for zoledronic acid and undetermined for denosumab due to limited skeletal-related events. The overall rate of skeletal-related events was signifi cantly lower with denosumab (hazard ratio, 0.77; 95% CI, 0.66-0.89). 19 No large phase III trials have been conducted with denosumab in multiple myeloma; however, phase II data have led to ongoing phase III trials.
Adverse effects with denosumab most commonly include nausea, bone pain, and anemia (Table) . In clinical studies conducted by Fizazi et al, 20 8% and 3% of patients developed grade 3 and grade 4 hypocalcemia, respectively. Other less common side effects include upper respiratory infections, arthralgia, hypertension, and urinary tract infections. Longterm monitoring of this therapy will be required to determine if osteonecrosis of the jaw and other toxicities become a complication of this treatment. 
CONCLUSION
